ODTX Revenue Flow
Filed revenue amounts for 2026-04-01 to 2026-06-30. Coverage is partial. Unconnected amounts are separate disclosures; they must not be added together.
- 2026-06-30: Revenue $0.00; Research and development $36.23M; Operating expenses $55.47M; Income tax -$8.00K.
- 2026-03-31: Revenue $0.00; Research and development $32.32M; Operating expenses $39.78M; Income tax $63.00K.
- 2025-06-30: Revenue $959.00K; Research and development $30.23M; Operating expenses $42.88M; Income tax $30.00K.
- 2025-03-31: Revenue $1.92M; Research and development $38.77M; Operating expenses $41.08M; Income tax $140.00K.
Revenue flow
Separate filed amounts; connecting flows are not established. Components and totals may overlap.
Finer product or service dollar figures and nonoverlapping groupings are shown only where supported by the retained filing evidence. Growth percentages are never converted to revenue dollars.
Historical revenue and expense breakdown
Revenue and expense 3 month
| Period end | Revenue | Research and development | Operating expenses | Income tax | Net income |
|---|---|---|---|---|---|
| 2026-06-30 | $0.00 | $36.23M | $55.47M | -$8.00K | -$52.79M |
| 2026-03-31 | $0.00 | $32.32M | $39.78M | $63.00K | -$38.26M |
| 2025-06-30 | $959.00K | $30.23M | $42.88M | $30.00K | -$41.23M |
| 2025-03-31 | $1.92M | $38.77M | $41.08M | $140.00K | -$38.44M |
Revenue and expense 6 month
| Period end | Revenue | Research and development | Operating expenses | Income tax | Net income |
|---|---|---|---|---|---|
| 2026-06-30 | $0.00 | $68.55M | $95.25M | $55.00K | -$91.05M |
| 2025-06-30 | $2.88M | $69.00M | $83.96M | $170.00K | -$79.67M |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Cullinan Therapeutics, Inc. (CGEM) | United States | $0.993B | -5.72 |
| Monte Rosa Therapeutics, Inc. (GLUE) | United States | $1.002B | -12.81 |
| Sana Biotechnology, Inc. (SANA) | United States | $0.886B | -4.92 |
| Candel Therapeutics, Inc. (CADL) | United States | $0.885B | -8.86 |
| MeiraGTx Holdings plc (MGTX) | United States | $1.061B | 16.10 |
| Vor Biopharma Inc. (VOR) | United States | $1.091B | 1.60 |
| Attovia Therapeutics, Inc. (ATTO) | United States | $0.828B | |
| Solid Biosciences Inc. (SLDB) | United States | $0.802B | -5.07 |
| Replimune Group, Inc. (REPL) | United States | $1.186B | -3.13 |
| 4D Molecular Therapeutics, Inc. (FDMT) | United States | $0.733B | -4.10 |